Search Results

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China.

• Authors : Jia, Caifeng¹ (AUTHOR); Zhang, Sen² (AUTHOR); Wang, Jie³ (AUTHOR)

• Source: Scientific Reports. 4/14/2025, Vol. 15 Issue 1, p1-13. 13p.

Record details

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China.

• Authors : Jiang, Hanfang¹ (AUTHOR) ; Zhong, Jianxin¹ (AUTHOR); Wang, Jing¹ (AUTHOR)

• Source: Cancer Medicine. May2024, Vol. 13 Issue 10, p1-19. 19p.

Record details

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.

• Authors : Chen, Lan¹ (AUTHOR); Yan, Xi² (AUTHOR) ; Luo, Ting² (AUTHOR)

• Source: Cancer Medicine. May2024, Vol. 13 Issue 10, p1-10. 10p.

Record details

Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.

• Authors : Jiang, Kuikui¹ (AUTHOR); Hong, Ruoxi¹ (AUTHOR); Xia, Wen¹ (AUTHOR)

• Source: Cancer Research & Treatment. Apr2024, Vol. 56 Issue 2, p513-521. 9p.

Record details

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.

• Authors : Wang, Wei^1,2 (AUTHOR); Lei, Wenqian³ (AUTHOR); Fang, Ziru¹ (AUTHOR)

• Source: BMC Cancer. 1/2/2024, Vol. 24 Issue 1, p1-13. 13p.

Record details

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China.

• Authors : Liu, Shixian^1,2,3 (AUTHOR); Wang, Kaixuan⁴ (AUTHOR); Chen, Hao^1,2,3 (AUTHOR)

• Source: Cost Effectiveness & Resource Allocation. 3/19/2025, Vol. 23 Issue 1, p1-8. 8p.

Record details

晚期乳腺癌基因检测临床应用指南 (2025版).

• Authors : 袁芃¹ ; 徐兵河²

• Source: Chinese Journal of Oncology. Oct2025, Vol. 47 Issue 10, p946-960. 15p.

Record details

A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer.

• Authors : Jiayi Huang¹; Xue Bai¹; Xiaofeng Xie¹

• Source: Oncologie (Tech Science Press). 2022, Vol. 24 Issue 1, p131-145. 15p.

Record details

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study.

• Authors : Xie, Yizhao¹ (AUTHOR); Ge, Rui² (AUTHOR); Sang, Die³ (AUTHOR)

• Source: Cancer Medicine. May2020, Vol. 9 Issue 9, p2981-2988. 8p.

Record details

Association of type 2 diabetes mellitus with histopathological features of Non-metastatic breast cancer in Chinese women: a retrospective Cross-sectional study.

• Authors : Liu L; The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. .; Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. .

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/pathology ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology

• Source: Scientific reports [Sci Rep] 2025 Aug 05; Vol. 15 (1), pp. 28645. Date of Electronic Publication: 2025 Aug 05.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details